Please use this identifier to cite or link to this item:
|Web of Science®
|Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach
Vaz de Melo, J.
|BBA: Proteins and Proteomics, 2010; 1804(10):1974-1987
|Elsevier Science BV
|Irene Colavita, Nicola Esposito, Rosanna Martinelli, Francesca Catanzano, Junia V. Melo, Fabrizio Pane, Margherita Ruoppolo, Francesco Salvatore
|Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease. A major concern in imatinib treatment is the emergence of resistance to the drug. Here we used the imatinib-resistant KCL22R and imatinib-sensitive KCL22S cells in which none of the known resistance mechanisms has been detected and hence novel Bcr-Abl activity-independent mechanisms could be envisaged. We characterized proteins that were differentially expressed between the KCL22R and KCL22S cells. Using two-dimensional differential gel electrophoresis coupled with mass spectrometry and Western blot analysis we identified 51 differentially expressed proteins: 27 were over-expressed and 24 were under-expressed in KCL22R versus KCL22S cells. Several of these proteins are likely to be involved in such survival mechanisms as modulation of redox balance and activation of anti-apoptotic pathways mediated by NF-kappaB and Ras-MAPK signaling. The data reported may be useful for further studies on mechanisms of imatinib resistance and for the screening of biomarkers to develop new combinatorial therapeutic approaches.
2D differential gel electrophoresis
Chronic myeloid leukemia
|Copyright © 2010 Elsevier B.V. All rights reserved.
|Appears in Collections:
|Animal and Veterinary Sciences publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.